JP2010526540A - 耐熱性生物活性組成物 - Google Patents
耐熱性生物活性組成物 Download PDFInfo
- Publication number
- JP2010526540A JP2010526540A JP2010507718A JP2010507718A JP2010526540A JP 2010526540 A JP2010526540 A JP 2010526540A JP 2010507718 A JP2010507718 A JP 2010507718A JP 2010507718 A JP2010507718 A JP 2010507718A JP 2010526540 A JP2010526540 A JP 2010526540A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- hydrogel
- hydrogel matrix
- bioactive
- bioactive composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 239000000017 hydrogel Substances 0.000 claims abstract description 125
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 85
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 84
- 239000011159 matrix material Substances 0.000 claims abstract description 46
- 239000011148 porous material Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 229940088598 enzyme Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 238000009997 thermal pre-treatment Methods 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 4
- 102000003992 Peroxidases Human genes 0.000 claims description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 102000013142 Amylases Human genes 0.000 claims description 3
- 108010065511 Amylases Proteins 0.000 claims description 3
- 102000004882 Lipase Human genes 0.000 claims description 3
- 108090001060 Lipase Proteins 0.000 claims description 3
- 239000004367 Lipase Substances 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 235000019418 amylase Nutrition 0.000 claims description 3
- 235000019421 lipase Nutrition 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 239000004382 Amylase Substances 0.000 claims description 2
- 108010059892 Cellulase Proteins 0.000 claims description 2
- 101710088194 Dehydrogenase Proteins 0.000 claims description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 101710172711 Structural protein Proteins 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 claims description 2
- 102000003425 Tyrosinase Human genes 0.000 claims description 2
- 229940106157 cellulase Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229960001340 histamine Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims 1
- 108010014251 Muramidase Proteins 0.000 claims 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 1
- 239000012867 bioactive agent Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960000274 lysozyme Drugs 0.000 claims 1
- 239000004325 lysozyme Substances 0.000 claims 1
- 235000010335 lysozyme Nutrition 0.000 claims 1
- 108010015776 Glucose oxidase Proteins 0.000 description 51
- 239000004366 Glucose oxidase Substances 0.000 description 50
- 229940116332 glucose oxidase Drugs 0.000 description 50
- 235000019420 glucose oxidase Nutrition 0.000 description 50
- 229920000642 polymer Polymers 0.000 description 41
- 230000000694 effects Effects 0.000 description 40
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 17
- 229940079593 drug Drugs 0.000 description 12
- 229920002521 macromolecule Polymers 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000783419 Naja kaouthia Alpha-cobratoxin Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- LKDMKWNDBAVNQZ-WJNSRDFLSA-N 4-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-WJNSRDFLSA-N 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 3
- FSSYNTJUYWSXFS-UHFFFAOYSA-N n-ethyl-4-[4-(ethylamino)phenyl]aniline Chemical compound C1=CC(NCC)=CC=C1C1=CC=C(NCC)C=C1 FSSYNTJUYWSXFS-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 2
- LPDSNGAFAJYVKH-UHFFFAOYSA-N 4-(4-aminophenyl)-2,3-dichloroaniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C(Cl)=C1Cl LPDSNGAFAJYVKH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006355 external stress Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 239000003505 polymerization initiator Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001361 allenes Chemical class 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- -1 calcium Antagonists Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 238000007816 calorimetric assay Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- UZZYXUGECOQHPU-UHFFFAOYSA-M n-octyl sulfate Chemical compound CCCCCCCCOS([O-])(=O)=O UZZYXUGECOQHPU-UHFFFAOYSA-M 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940067739 octyl sulfate Drugs 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000004854 plant resin Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- UZZYXUGECOQHPU-UHFFFAOYSA-N sulfuric acid monooctyl ester Natural products CCCCCCCCOS(O)(=O)=O UZZYXUGECOQHPU-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本願は、2008年5月9日に出願した米国特許出願第12/118,171号における優先権を主張する。その内容は参考により本明細書中に組み込まれている。
本発明は、生物活性材料を安定化するための組成物及びその方法、特にヒドロゲルに固定化された生物活性材料を安定化するための熱処理に関する。
生物活性高分子、例えばタンパク質、核酸及び機能酵素は、生物医学的及び工業的な適用の様々な観点において広く利用されている。例えば、核酸はポリメラーゼ連鎖反応のための遺伝子の鋳型として利用されており、一方タンパク質は、洗剤の分解洗浄能力を亢進するために洗剤混合物において使用されている。
生物活性高分子は、生体細胞内で生物学的な機能性を有する高分子を意味してよい。生物活性高分子は、核酸、消化タンパク質、及び機能酵素を含んでよい。以下に記載されるそのほかの成分も含んでよい。
代表的なタンパク質である、グルコースオキシダーゼ(GOx、5mg)を2mlの0.1M、pH7.0のリン酸ナトリウム緩衝液に溶かし、その後1.2mlの脱イオン水、100μlの過硫酸アンモニウム(DI水中10%w/v)及び6.8mlの30%アクリルアミド/ビス溶液(Bio-Rad Laboratoriesから購入)と混合する。ヒドロゲル重合は、4μlのNNN’N’−テトラメチルエチレンジアミン(TEMED)を室温で添加することにより開始する。ピペットを用いてヒドロゲル溶液を注意深くガラスエンクロージャー(8.3×7×0.075cm3)に添加し、そして少なくとも4時間保持し、重合を完了させる。タンパク質含有ヒドロゲルを、16.2mmの直径を有する小ディスクに押し出し、これをさらに使用するためにリンスし、そして乾燥させる。
遊離GOxと比較して、捕捉されたGOxの場合には増大した熱安定性が観察される。熱安定性の分析は温度調節オーブン中で行う。ヒドロゲル−タンパク質ディスクを80℃で様々な時間インキュベートし、そしてこれらの残留活性を例5に記載されるプロトコルに従い測定する。天然の乾燥タンパク質の安定性もまた対照として試験する。
ポリアクリルアミドヒドロゲル中のα−CTの捕捉は、以下の手順により行われる:0.5〜10mgのα−CTを0.42mlの0.01MのpH7.5の酢酸ナトリウム緩衝液に添加し、その後該緩衝液混合物を9.33mlの30%アクリルアミド/ビス溶液及び0.25mlのDI H2Oと混合し、全モノマー濃度がT=28%及び架橋剤濃度がC=5%である10mlの溶液を作成する。重合は、100μlの新しく調製した過硫酸アンモニウム(脱イオン水中10%w/v)及び4μlのTEMEDを室温で添加することにより、ガラスエンクロージャー(8.3×7×0.075cm3)中で開始する。ヒドロゲル中に酵素を捕捉するための完全なゲル化に少なくとも4時間は必要とする。ガラスエンクロージャーから生じたヒドロゲルプレートを、さらなる試験のために16mmの直径を伴う小ディスクに押し出した。
天然酵素のために、50μlの酵素溶液(1mg/ml)を2.44mlの酢酸ナトリウム緩衝液及び13μlの160mM SAAPPN(N−スクシニル−Ala−Ala−Pro−Phe−p−ニトロアニリド)原液をキュベット中で混合する。反応活性は、410nmの吸光度をモニタリングすることにより測定する。
例4及び6に記載される活性試験において、冠水したヒドロゲルディスクを数分間反応混合物から取り出し、その後各々の反応バイアル中に再び浸す。この工程は、活性アッセイを行う間、何回か繰り返すことができる。ヒドロゲルディスクの取り出し(withdrawal)直後の反応混合物の吸光度は、ヒドロゲル捕捉GOxについて500nmにおけるUV−Vにより測定され、そしてヒドロゲル捕捉α−CTについて410nmにおけるUV−Vにより測定される。図11からわかるように、それぞれの取り出し後において吸光度の有意な増加は何ら観察されなかった。この観察は、活性アッセイにおいてディスクから反応溶液への明らかなタンパク質の漏出が存在しないことを示す。
例1及び5に示されるとおり、ヒドロゲル捕捉グルコースオキシダーゼ(GOx)及びα−キモトリプシンを調製した。治験比較目的のために、生じたヒドロゲルディスクを以下に示す処理にかけた。
例1に示されるとおり、生物活性高分子、例えばGOxを含有するヒドロゲルディスクを調製し、そして例3に示されるとおり熱処理した。高温度及び極性溶媒の組み合わせを含む厳しい条件下において安定性を調査した。具体的には、前処理したヒドロゲルディスクを10mlの純粋なエタノール中でインキュベートする。エタノール中に最大1時間浸漬させ、その後これらのディスクを75℃の温度のオーブンに置いた。ディスクは、活性測定のためにオーブン内から定期的に移動させた。
例1に示されるとおり、生物活性高分子、例えばGOxを含有するヒドロゲルディスクを調製し、そして例3に示されるとおり熱処理した。前処理後、ヒドロゲル捕捉GOxの安定性をUV光下において調査した。具体的には、前処理したヒドロゲルディスクを、365nmの長波長ランプ(8 watts, UVL-18, UVP, Upland, California, USA)で12時間照射した。UV照射後、残留活性を測定するための活性アッセイのために、該ヒドロゲルディスクを移した。熱前処理ヒドロゲル捕捉GOxについて、UV照射の前後に明らかな活性の喪失は見られなかった。
Claims (12)
- 生物活性組成物であって:
多孔性ヒドロゲルマトリックス;
該多孔性ヒドロゲルマトリックス中に固定された少なくとも1つのタンパク質、
を含んで成り、該タンパク質が、対応する遊離の消化タンパク質の半減期よりも少なくとも1000倍長い半減期を有することを特徴とする、生物活性組成物。 - 前記タンパク質が、最大110℃の温度に対する暴露後に生物学的活性を維持する、請求項1に記載の生物活性組成物。
- 前記タンパク質が、プロテアーゼ、アミラーゼ、セルラーゼ、リパーゼ、ペルオキシダーゼ、チロシナーゼ、グリコシダーゼ、ヌクレアーゼ、アルドラーゼ、ホスファターゼ、スファターゼ、デヒドロゲナーゼ、及びリゾチーム、ならびにこれらの組み合わせから成る群から選択される、請求項1に記載の生物活性組成物。
- 抗体、核酸、脂肪酸、ホルモン、ビタミン、ミネラル、構造タンパク質、酵素、ならびにヒスタミン遮断薬及びヘパリンを含む治療剤から成る群から選択される生物活性剤をさらに含む、請求項1に記載の生物活性組成物。
- 前記ヒドロゲルマトリックスの細孔が体積V1を定義し、そして少なくとも1つのタンパク質が該タンパク質の集合的な3次元サイズにより定義される全体積V2を有し、ここで(V1−V2)/V1の割合が20%以下であることを特徴とする、請求項1に記載の生物活性組成物。
- 前記少なくとも1つのタンパク質が、約110℃の温度における乾燥加熱に暴露した場合に300日以上の半減期を有する、請求項1に記載の生物活性組成物。
- 前記ヒドロゲルマトリックスが、該ヒドロゲルマトリックスの10重量%以下の水分含有量を含み、そしてここで前記消化タンパク質が該ヒドロゲルマトリックスの0.2〜5.0乾燥重量%であることを特徴とする、請求項1に記載の生物活性組成物。
- 生物活性組成物を安定化するための方法であって:
タンパク質分子の周りにヒドロゲルの細孔を形成する工程;及び
該ヒドロゲルマトリックスの細孔内の水分含有量を低下させ、その一方でタンパク質分子の生物活性を保持する工程、
を含んでなる方法。 - 前記ヒドロゲルマトリックスが、初期水分含有量W1を有し、そして該ヒドロゲルマトリックスを熱前処理にかけ、改変した水分含有量W2を有する改変したヒドロゲルマトリックスを形成する工程を含み、ここで(W1−W2)/W1が30%以上であることを特徴とする、請求項8に記載の方法。
- 前記(W1−W2)/W1が50%以上である、請求項9に記載の方法。
- 前記熱前処理が、ヒドロゲルマトリックスを20〜110℃の温度で24時間〜7日間加熱する工程を含んでなる、請求項8に記載の方法。
- 生物活性組成物であって:
体積V1を定義するヒドロゲルマトリックスの細孔;
該ヒドロゲルマトリックスの細孔中に固定化される少なくとも1つのタンパク質を含んでなり、ここで該タンパク質が該タンパク質の集合的な3次元サイズにより定義される全体積V2を有し、ここで(V1−V2)/V1の割合が20%以下であることを特徴とする、生物活性組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91755907P | 2007-05-11 | 2007-05-11 | |
US60/917,559 | 2007-05-11 | ||
US12/118,171 | 2008-05-09 | ||
US12/118,171 US8222015B2 (en) | 2007-05-11 | 2008-05-09 | Heat resistant bioactive composition |
PCT/US2008/063378 WO2008141263A1 (en) | 2007-05-11 | 2008-05-12 | Heat resistant bioactive composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010526540A true JP2010526540A (ja) | 2010-08-05 |
JP5592254B2 JP5592254B2 (ja) | 2014-09-17 |
Family
ID=40002633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010507718A Active JP5592254B2 (ja) | 2007-05-11 | 2008-05-12 | 耐熱性生物活性組成物 |
Country Status (4)
Country | Link |
---|---|
US (2) | US8222015B2 (ja) |
JP (1) | JP5592254B2 (ja) |
DE (1) | DE112008001157B4 (ja) |
WO (1) | WO2008141263A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012095648A (ja) * | 2010-10-13 | 2012-05-24 | Toyota Motor Engineering & Manufacturing North America Inc | 安定化されたタンパク質を含む生体活性組成物及びその製造方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090238811A1 (en) * | 2002-09-09 | 2009-09-24 | Mcdaniel C Steven | Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials |
US9828597B2 (en) | 2006-11-22 | 2017-11-28 | Toyota Motor Engineering & Manufacturing North America, Inc. | Biofunctional materials |
US11015149B2 (en) | 2010-06-21 | 2021-05-25 | Toyota Motor Corporation | Methods of facilitating removal of a fingerprint |
US10988714B2 (en) | 2010-06-21 | 2021-04-27 | Regents Of The University Of Minnesota | Methods of facilitating removal of a fingerprint from a substrate or a coating |
US9121016B2 (en) | 2011-09-09 | 2015-09-01 | Toyota Motor Engineering & Manufacturing North America, Inc. | Coatings containing polymer modified enzyme for stable self-cleaning of organic stains |
US9388370B2 (en) | 2010-06-21 | 2016-07-12 | Toyota Motor Engineering & Manufacturing North America, Inc. | Thermolysin-like protease for cleaning insect body stains |
US8796009B2 (en) | 2010-06-21 | 2014-08-05 | Toyota Motor Engineering & Manufacturing North America, Inc. | Clearcoat containing thermolysin-like protease from Bacillus stearothermophilus for cleaning of insect body stains |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61104787A (ja) * | 1984-10-26 | 1986-05-23 | Toyo Jozo Co Ltd | Pvaゲルによる多孔性固定化酵素含有物の製法 |
JPS626682A (ja) * | 1985-07-02 | 1987-01-13 | Canon Inc | 固定化担体 |
JPH02273183A (ja) * | 1983-11-16 | 1990-11-07 | Hitachi Ltd | 生体触媒固定化多孔質ゲル化物の製法 |
JP2005224160A (ja) * | 2004-02-12 | 2005-08-25 | Yakult Honsha Co Ltd | 固定化微生物担体または固定化酵素担体の製造方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3622533A (en) * | 1967-08-30 | 1971-11-23 | American Cyanamid Co | Polyacrylamide gels containing latent thermal degradation inhibitor |
US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
EP0363504A1 (en) | 1988-10-10 | 1990-04-18 | Dräger Nederland B.V. | Method of providing a substrate with a layer comprising a polyvinylbased hydrogel and a biochemically active material |
US5482996A (en) | 1993-12-08 | 1996-01-09 | University Of Pittsburgh | Protein-containing polymers and a method of synthesis of protein-containing polymers in organic solvents |
US6004583A (en) | 1995-03-22 | 1999-12-21 | Orex Pharmaceutical Development Corp. | Protein-containing polymer composition for oral administration |
US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
ATE254612T1 (de) | 1996-11-28 | 2003-12-15 | New Japan Chem Co Ltd | Zuckerderivate, geliermittel, geliermittelzubereitungen, verfahren zu ihrer herstellung und gelzubereitungen |
US5989899A (en) | 1996-12-23 | 1999-11-23 | Genencor International, Inc. | Oversized cellulase compositions for use in detergent compositions and in the treatment of textiles |
DE19832547A1 (de) | 1998-07-21 | 2000-01-27 | Basf Ag | Enzymhaltige Polymere |
DE60040190D1 (de) | 1999-01-28 | 2008-10-23 | Indevus Pharmaceuticals Inc | Hydrogel zusammensetzungen, geeignet zur verzögerten freisetzung von makromolekülen sowie verfahren zur herstellung derselben. |
DE19903655A1 (de) | 1999-01-29 | 2000-08-10 | Beiersdorf Ag | Proteinhaltige Hydrogele |
CA2364570A1 (en) * | 1999-04-09 | 2000-10-19 | The Regents Of The University Of Michigan | Preparing porous hydrogel products |
US6617014B1 (en) | 1999-09-01 | 2003-09-09 | Hydrophilix, Llc | Foam composite |
US6759220B1 (en) | 1999-11-17 | 2004-07-06 | Agentase, Llc | Enzyme-containing polyurethanes |
US6310105B1 (en) | 2000-02-15 | 2001-10-30 | Wisconsin Alumni Research Foundation | Carboxyl-modified superabsorbent protein hydrogel |
US7118737B2 (en) * | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
US6596402B2 (en) | 2000-12-29 | 2003-07-22 | Kimberly-Clark Worldwide, Inc. | Absorbent, lubricious coating and articles coated therewith |
US20050276858A1 (en) * | 2001-04-23 | 2005-12-15 | Kao Weiyuan J | Bifunctional-modified hydrogels |
US6844028B2 (en) | 2001-06-26 | 2005-01-18 | Accelr8 Technology Corporation | Functional surface coating |
JP2006502695A (ja) * | 2002-02-15 | 2006-01-26 | ダイヴァーサ コーポレイション | キメラカニューレタンパク質、それをコードする核酸、その製造方法およびその使用方法 |
WO2003089506A1 (en) * | 2002-04-22 | 2003-10-30 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
WO2004108917A1 (en) | 2003-06-09 | 2004-12-16 | Insense Limited | Method for stabilization of enzymes during exposure to sterilizing radation |
WO2005060668A2 (en) | 2003-12-18 | 2005-07-07 | The Trustees Of Columbia University In The City Ofnew York | Methods of modifying surfaces |
US7968085B2 (en) * | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
US20060188940A1 (en) * | 2005-02-22 | 2006-08-24 | Michael Cima | Combinatorial hydrogel formulation |
-
2008
- 2008-05-09 US US12/118,171 patent/US8222015B2/en active Active
- 2008-05-12 DE DE112008001157.5T patent/DE112008001157B4/de active Active
- 2008-05-12 JP JP2010507718A patent/JP5592254B2/ja active Active
- 2008-05-12 WO PCT/US2008/063378 patent/WO2008141263A1/en active Application Filing
-
2012
- 2012-06-18 US US13/525,714 patent/US8361768B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02273183A (ja) * | 1983-11-16 | 1990-11-07 | Hitachi Ltd | 生体触媒固定化多孔質ゲル化物の製法 |
JPS61104787A (ja) * | 1984-10-26 | 1986-05-23 | Toyo Jozo Co Ltd | Pvaゲルによる多孔性固定化酵素含有物の製法 |
JPS626682A (ja) * | 1985-07-02 | 1987-01-13 | Canon Inc | 固定化担体 |
JP2005224160A (ja) * | 2004-02-12 | 2005-08-25 | Yakult Honsha Co Ltd | 固定化微生物担体または固定化酵素担体の製造方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012095648A (ja) * | 2010-10-13 | 2012-05-24 | Toyota Motor Engineering & Manufacturing North America Inc | 安定化されたタンパク質を含む生体活性組成物及びその製造方法 |
JP2017060480A (ja) * | 2010-10-13 | 2017-03-30 | トヨタ モーター エンジニアリング アンド マニュファクチャリング ノース アメリカ,インコーポレイティド | 安定化されたタンパク質を含む生体活性組成物及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2008141263A1 (en) | 2008-11-20 |
US8222015B2 (en) | 2012-07-17 |
DE112008001157T5 (de) | 2010-03-25 |
JP5592254B2 (ja) | 2014-09-17 |
US8361768B2 (en) | 2013-01-29 |
DE112008001157B4 (de) | 2015-07-16 |
US20120252090A1 (en) | 2012-10-04 |
US20080293117A1 (en) | 2008-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5592254B2 (ja) | 耐熱性生物活性組成物 | |
Zhang et al. | Encapsulation of lactase (β-galactosidase) into κ-carrageenan-based hydrogel beads: Impact of environmental conditions on enzyme activity | |
Alsarra et al. | Effects of preparative parameters on the properties of chitosan hydrogel beads containing Candida rugosa lipase | |
Mazzuca et al. | Cleaning of paper artworks: development of an efficient gel-based material able to remove starch paste | |
Singh et al. | Synthesis, characterization and swelling studies of pH responsive psyllium and methacrylamide based hydrogels for the use in colon specific drug delivery | |
Qi et al. | Glucose-sensitive microcapsules from glutaraldehyde cross-linked hemoglobin and glucose oxidase | |
Idris et al. | Immobilization of Baker's yeast invertase in PVA–alginate matrix using innovative immobilization technique | |
WO2008063902A2 (en) | Biofunctional materials | |
Sattar et al. | Agar-agar immobilization: An alternative approach for the entrapment of protease to improve the catalytic efficiency, thermal stability and recycling efficiency | |
Brahim et al. | Kinetics of glucose oxidase immobilized in p (HEMA)-hydrogel microspheres in a packed-bed bioreactor | |
Doretti et al. | PEG-modified glucose oxidase immobilized on a PVA cryogel membrane for amperometric biosensor applications | |
Coche-Guerente et al. | Sol− Gel Derived Composite Materials for the Construction of Oxidase/Peroxidase Mediatorless Biosensors | |
Saxena et al. | Biopolymer matrix for nano-encapsulation of urease–A model protein and its application in urea detection | |
Ghanem et al. | Immobilization of glucose oxidase in chitosan gel beads | |
Pulat et al. | Preparation and characterization of gelatin hydrogel support for immobilization of Candida Rugosa lipase | |
Scheja et al. | Glucose‐Triggered Insulin Release from Fe3+‐Cross‐linked Alginate Hydrogel: Experimental Study and Theoretical Modeling | |
Mazzuca et al. | How to tune a paper cleaning process by means of modified gellan hydrogels | |
Sáringer et al. | Papain adsorption on latex particles: charging, aggregation, and enzymatic activity | |
Zhang et al. | Tyrosinase-mediated dopamine polymerization modified magnetic alginate beads for dual-enzymes encapsulation: Preparation, performance and application | |
Mallardi et al. | General approach to the immobilization of glycoenzyme chains inside calcium alginate beads for bioassay | |
Riccardi et al. | Nanoarmoring of enzymes by interlocking in cellulose fibers with poly (acrylic acid) | |
Koeda et al. | Construction and characterization of protein-encapsulated electrospun fibermats prepared from a silica/poly (γ-glutamate) hybrid | |
JPH01240188A (ja) | 機能性有機薄膜 | |
EP2534483B1 (de) | Testanordnung | |
Vidinha et al. | Probing the microenvironment of sol–gel entrapped cutinase: The role of added zeolite NaY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110512 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130806 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140701 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140731 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5592254 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |